Intragenic mutations in SMN1 may contribute more significantly to clinical severity than SMN2 copy numbers in some spinal muscular atrophy (SMA) patients
Brain and Development2013Vol. 36(10), pp. 914–920
Citations Over TimeTop 16% of 2013 papers
Tomoto Yamamoto, Hideyuki Sato, Poh San Lai, Dian Kesumapramudya Nurputra, Nur Imma Fatimah Harahap, Satoru Morikawa, Noriyuki Nishimura, Takashi Kurashige, Tomohiko Ohshita, Hideki Nakajima, Hiroyuki Yamada, Yoshinobu Nishida, SOICHIRO TODA, Jun‐ichi Takanashi, Atsuko Takeuchi, Yumi Tohyama, Yuji Kubo, Kayoko Saito, Yasuhiro Takeshima, Masafumi Matsuo, Hisahide Nishio
Related Papers
- → Spinal Muscular Atrophy: New and Emerging Insights from Model Mice(2010)54 cited
- → SMN-Inducing Compounds For The Treatment Of Spinal Muscular Atrophy(2012)34 cited
- → Mammalian Models of Spinal Muscular Atrophy(2016)10 cited
- → Pharmacological and clinical profile of Onasemnogene Aveparvovec, the first gene therapy for spinal muscular atrophy (SMA)(2021)3 cited
- → Molecular genetics of spinal muscular atrophy(2023)1 cited